T1	PROC 87 106	evaluar la eficacia
#1	AnnotatorNotes T1	C1707887; Efficacy Study; Research Activity
T2	CHEM 140 150	vitamina D
#2	AnnotatorNotes T2	C0042866; vitamin D; Hormone · Pharmacologic Substance · Vitamin
T3	DISO 168 189	neumonía por COVID-19
T4	PROC 264 283	evaluar la eficacia
#3	AnnotatorNotes T4	C1707887; Efficacy Study; Research Activity
T5	CHEM 308 322	colecalciferol
#4	AnnotatorNotes T5	C0008318; cholecalciferol; Organic Chemical · Pharmacologic Substance · Vitamin | C3265062; vitamin D3; Organic Chemical · Pharmacologic Substance · Vitamin
T6	PROC 358 378	tratamiento estándar
#5	AnnotatorNotes T6	C2936643; Standard of Care; Health Care Activity
T7	DISO 396 417	neumonía por COVID-19
T8	CHEM 500 521	25-hidroxivitamina D3
#6	AnnotatorNotes T8	C0006657; calcifediol; Pharmacologic Substance · Vitamin
T9	PROC 583 607	consentimiento informado
#7	AnnotatorNotes T9	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T10	PROC 670 680	ingresados
#8	AnnotatorNotes T10	C0021629; Institutionalization; Health Care Activity | C0184666; Hospital admission; Health Care Activity
T11	PROC 685 696	diagnóstico
#9	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	PROC 767 780	microbiología
T13	DISO 784 792	COVID-19
#10	AnnotatorNotes T13	C5203670; COVID19 (disease); Disease or Syndrome
T14	DISO 828 836	síntomas
#11	AnnotatorNotes T14	C1457887; Symptoms; Sign or Symptom
T15	DISO 838 841	tos
#12	AnnotatorNotes T15	C0010200; Coughing; Sign or Symptom
T16	DISO 844 850	fiebre
#13	AnnotatorNotes T16	C0015967; Fever; Sign or Symptom
T17	PROC 970 993	métodos anticonceptivos
#14	AnnotatorNotes T17	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T18	PROC 857 878	saturación de oxígeno
#15	AnnotatorNotes T18	C0523807; Oxygen saturation measurement; Laboratory Procedure
T19	PROC 1801 1804	FGe
#16	AnnotatorNotes T19	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T20	PROC 1149 1167	prueba de embarazo
#17	AnnotatorNotes T20	C0032976; Pregnancy Tests; Diagnostic Procedure
T21	PROC 1273 1287	ensayo clínico
#18	AnnotatorNotes T21	C0008976; Clinical Trials; Research Activity
T22	CHEM 1292 1331	fármacos con potencial acción antiviral
T23	DISO 1337 1345	COVID-19
#19	AnnotatorNotes T23	C5203670; COVID19 (disease); Disease or Syndrome
T24	PROC 1359 1370	tratamiento
#20	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	DISO 1402 1421	fallo multiorgánico
#21	AnnotatorNotes T25	C0026766; Multiple Organ Failure; Pathologic Function
T26	PROC 1449 1469	ventilación mecánica
#22	AnnotatorNotes T26	C0199470; Mechanical ventilation; Therapeutic or Preventive Procedure
T27	DISO 1514 1531	hipersensibilidad
#23	AnnotatorNotes T27	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T28	CHEM 1552 1566	colecalciferol
#24	AnnotatorNotes T28	C0008318; cholecalciferol; Organic Chemical · Pharmacologic Substance · Vitamin | C3265062; vitamin D3; Organic Chemical · Pharmacologic Substance · Vitamin
T29	CHEM 1571 1581	excipiente
#25	AnnotatorNotes T29	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T30	CHEM 1582 1597	aceite de oliva
#26	AnnotatorNotes T30	C0069449; olive oil; Food · Organic Chemical
T31	DISO 1623 1636	hipercalcemia
#27	AnnotatorNotes T31	C0020437; Hypercalcemia; Disease or Syndrome
T32	DISO 1639 1653	hipercalciuria
#28	AnnotatorNotes T32	C0020438; Hypercalciuria; Finding
T33	DISO 1656 1672	Cálculos renales
#29	AnnotatorNotes T33	C0022650; Kidney Calculi; Disease or Syndrome | C0392525; Nephrolithiasis; Disease or Syndrome
T34	DISO 1674 1687	nefrolitiasis
#30	AnnotatorNotes T34	C0022650; Kidney Calculi; Disease or Syndrome | C0392525; Nephrolithiasis; Disease or Syndrome
T35	DISO 1689 1704	nefrocalcinosis
#31	AnnotatorNotes T35	C0027709; Nephrocalcinosis; Disease or Syndrome
T36	DISO 1723 1736	hipercalcemia
#32	AnnotatorNotes T36	C0020437; Hypercalcemia; Disease or Syndrome
T37	DISO 1762 1781	insuficiencia renal
#33	AnnotatorNotes T37	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T38	PROC 1827 1838	tratamiento
#34	AnnotatorNotes T38	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T39	PROC 1869 1880	diagnóstico
#35	AnnotatorNotes T39	C0011900; Diagnosis; Diagnostic Procedure
T40	DISO 1884 1922	intolerancia hereditaria a la fructosa
#36	AnnotatorNotes T40	C0016751; Hereditary fructose intolerance syndrome; Disease or Syndrome
T41	DISO 1924 1957	malabsorción de glucosa-galactosa
#37	AnnotatorNotes T41	C0865194; Intolerance or malabsorption of glucose-galactose; Disease or Syndrome
T42	CHEM 1977 1985	sacarosa
#38	AnnotatorNotes T42	C0038636; sucrose; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T43	DISO 2014 2025	Sarcoidosis
#39	AnnotatorNotes T43	C0036202; Sarcoidosis; Disease or Syndrome
T44	DISO 2028 2047	Hiperparatiroidismo
#40	AnnotatorNotes T44	C0020502; Hyperparathyroidism; Disease or Syndrome
T45	PROC 2258 2282	consentimiento informado
#41	AnnotatorNotes T45	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T46	PROC 2130 2140	evaluación
#42	AnnotatorNotes T46	C1261322; Evaluation procedure; Health Care Activity
T47	DISO 1960 1985	insuficiencia de sacarosa
T48	PROC 44 80	Ensayo clínico aleatorizado, abierto
T49	PROC 489 521	Niveles de 25-hidroxivitamina D3
T50	PROC 211 257	Ensayo clínico aleatorizado, FASE III, abierto
T51	PROC 290 304	administración
#43	AnnotatorNotes T51	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T52	DISO 439 460	NEUMONIA POR COVID-19
T53	DISO 700 708	neumonía
#44	AnnotatorNotes T53	C0032285; Pneumonia; Disease or Syndrome
T54	PROC 2319 2341	traslado a otro centro
#45	AnnotatorNotes T54	C0030704; Patient Transfer; Health Care Activity
T55	CHEM 1375 1385	vitamina D
#46	AnnotatorNotes T55	C0042866; vitamin D; Hormone · Pharmacologic Substance · Vitamin
T56	CHEM 1535 1551	principio activo
#47	AnnotatorNotes T56	C1372955; Active ingredient; Chemical Viewed Functionally
T57	ANAT 1665 1672	renales
#48	AnnotatorNotes T57	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T58	ANAT 1776 1781	renal
#49	AnnotatorNotes T58	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T59	CHEM 1843 1851	digoxina
#50	AnnotatorNotes T59	C0012265; digoxin; Organic Chemical · Pharmacologic Substance
T60	CHEM 1914 1922	fructosa
#51	AnnotatorNotes T60	C0016745; fructose; Organic Chemical · Pharmacologic Substance
T61	CHEM 1940 1947	glucosa
#52	AnnotatorNotes T61	C0017725; glucose; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T62	CHEM 1948 1957	galactosa
#53	AnnotatorNotes T62	C0016945; galactose; Biologically Active Substance · Organic Chemical
T63	DISO 2402 2415	fallecimiento
#54	AnnotatorNotes T63	C1306577; Death (finding); Finding | C1546956; Patient Outcome - Died; Finding
T64	Date 12 16	2020
T65	Dose 125 136	dosis altas
#55	AnnotatorNotes T65	C0444956; High dose; Quantitative Concept
T66	LIVB 154 163	pacientes
#56	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T67	Dose 325 336	altas dosis
#57	AnnotatorNotes T67	C0444956; High dose; Quantitative Concept
T68	Route 341 349	vía oral
#58	AnnotatorNotes T68	C1527415; Oral Route of Drug administration; Functional Concept
T69	LIVB 382 391	pacientes
#59	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	LIVB 611 617	Hombre
#60	AnnotatorNotes T70	C0025266; Male population group; Population Group
T71	LIVB 620 627	mujeres
#61	AnnotatorNotes T71	C0043210; Woman; Population Group
T72	Age 637 656	≥18 años y ≤85 años
T73	LIVB 660 669	Pacientes
#62	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T74	Duration 816 824	> 7 días
T75	CHEM 871 878	oxígeno
#63	AnnotatorNotes T75	C0030054; oxygen; Biologically Active Substance · Element, Ion, or Isotope · Pharmacologic Substance
T76	LIVB 904 911	hombres
#64	AnnotatorNotes T76	C0025266; Male population group; Population Group
T77	LIVB 914 921	mujeres
#65	AnnotatorNotes T77	C0043210; Woman; Population Group
T78	PHYS 926 948	capacidad reproductiva
#66	AnnotatorNotes T78	C0232896; Reproductive function; Physiologic Function
T79	Duration 1013 1024	los 30 días
T80	LIVB 1070 1091	mujeres participantes
#67	AnnotatorNotes T80	C0043210; Women; Population Group + C4554048; Study Participant; Population Group
T81	PHYS 1110 1132	capacidad reproductiva
#68	AnnotatorNotes T81	C0232896; Reproductive function; Physiologic Function
T82	Neg_cue 1168 1176	negativa
T83	LIVB 1236 1245	Pacientes
#69	AnnotatorNotes T83	C0030705; Patients; Patient or Disabled Group
T85	LIVB 1425 1434	Pacientes
#70	AnnotatorNotes T85	C0030705; Patients; Patient or Disabled Group
T86	LIVB 1500 1509	Pacientes
#71	AnnotatorNotes T86	C0030705; Patients; Patient or Disabled Group
T87	LIVB 1609 1618	Pacientes
#72	AnnotatorNotes T87	C0030705; Patients; Patient or Disabled Group
T88	LIVB 1709 1718	pacientes
#73	AnnotatorNotes T88	C0030705; Patients; Patient or Disabled Group
T89	Duration 1737 1744	crónica
#74	AnnotatorNotes T89	C0205191; chronic; Temporal Concept
T90	LIVB 1748 1757	Pacientes
#75	AnnotatorNotes T90	C0030705; Patients; Patient or Disabled Group
T91	LIVB 1814 1823	Pacientes
#76	AnnotatorNotes T91	C0030705; Patients; Patient or Disabled Group
T92	LIVB 1855 1864	Pacientes
#77	AnnotatorNotes T92	C0030705; Patients; Patient or Disabled Group
T93	PHYS 1990 1999	Gestación
#78	AnnotatorNotes T93	C0032961; Pregnancy; Organism Function
T94	PHYS 2002 2011	lactancia
#79	AnnotatorNotes T94	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T95	LIVB 2050 2059	Pacientes
#80	AnnotatorNotes T95	C0030705; Patients; Patient or Disabled Group
T97	LIVB 2152 2164	investigador
#81	AnnotatorNotes T97	C0035173; Research Personnel; Professional or Occupational Group
T98	LIVB 2168 2175	Sujetos
#82	AnnotatorNotes T98	C0681850; Study Subject; Group
T99	Neg_cue 2180 2182	no
T100	Neg_cue 2235 2247	incapaces de
T101	LIVB 2286 2295	Pacientes
#83	AnnotatorNotes T101	C0030705; Patients; Patient or Disabled Group
T102	Duration 2345 2368	las siguientes 96 horas
T103	LIVB 2372 2381	Pacientes
#84	AnnotatorNotes T103	C0030705; Patients; Patient or Disabled Group
T104	PHYS 2199 2209	comprender
#85	AnnotatorNotes T104	C0162340; Comprehension; Mental Process
T105	Duration 2419 2443	las próximas 24-48 horas
T106	PHYS 1159 1167	embarazo
#86	AnnotatorNotes T106	C0032961; Pregnancy; Organism Function
T84	PROC 1048 1054	visita
#87	AnnotatorNotes T84	C1512346; Patient Visit; Health Care Activity
T96	Quantifier_or_Qualifier 1041 1047	última
A1	Assertion T106 Negated
A2	Assertion T45 Negated
A3	Assertion T104 Negated
A4	Status T27 History_of
#89	AnnotatorNotes T48	C1709323; Open Label Study; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
#90	AnnotatorNotes T50	C1709323; Open Label Study; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity + C0282461; Phase 3 Clinical Trials; Research Activity 
#91	AnnotatorNotes T7	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#92	AnnotatorNotes T3	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#93	AnnotatorNotes T52	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#94	AnnotatorNotes T49	C4722189; 25-Hydroxyvitamin D3 Measurement; Laboratory Procedure 
#95	AnnotatorNotes T12	C0085672; Microbiology procedure; Laboratory Procedure 
T107	Observation 2100 2123	incluidos en el estudio
A5	Assertion T107 Negated
#88	AnnotatorNotes T107	C1302261; Patient eligible for clinical trial; Finding (?)
T108	Neg_cue 2085 2087	no
T109	Quantifier_or_Qualifier 1322 1331	antiviral
A6	Assertion T109 Speculated
#96	AnnotatorNotes T109	C4552591; Antiviral (disposition); Qualitative Concept
T110	Spec_cue 1305 1314	potencial
T111	Observation 539 570	acepte participar en el estudio
R1	Negation Arg1:T82 Arg2:T106	
R2	Speculation Arg1:T110 Arg2:T109	
R3	Negation Arg1:T108 Arg2:T107	
R4	Negation Arg1:T99 Arg2:T104	
R5	Negation Arg1:T100 Arg2:T45	
T112	CONC 2213 2232	hoja de información
#97	AnnotatorNotes T112	C3890404; Clinical Trial Subject Information Form; Intellectual Product (?)
R7	Experiences Arg1:T95 Arg2:T46	
R8	Before Arg1:T46 Arg2:T107	
R9	Experiences Arg1:T98 Arg2:T104	
R10	Overlap Arg1:T104 Arg2:T45	
T113	CONC 2306 2315	se prevea
#98	AnnotatorNotes T113	C1301732; Planned; Functional Concept
R11	Overlap Arg1:T54 Arg2:T102	
R12	Experiences Arg1:T101 Arg2:T54	
T114	CONC 2392 2401	se prevea
#99	AnnotatorNotes T114	C1301732; Planned; Functional Concept
R13	Overlap Arg1:T63 Arg2:T105	
R14	Experiences Arg1:T103 Arg2:T63	
R15	Has_Dose_or_Strength Arg1:T2 Arg2:T65	
R16	Experiences Arg1:T66 Arg2:T2	
R17	Experiences Arg1:T66 Arg2:T3	
R18	Used_for Arg1:T5 Arg2:T51	
R19	Has_Dose_or_Strength Arg1:T5 Arg2:T67	
R20	Has_Route_or_Mode Arg1:T5 Arg2:T68	
R21	Combined_with Arg1:T51 Arg2:T6	
R22	Experiences Arg1:T69 Arg2:T51	
R23	Experiences Arg1:T69 Arg2:T7	
T115	Result_or_Value 522 532	< 30 ng/mL
R24	Has_Result_or_Value Arg1:T49 Arg2:T115	
R25	Overlap Arg1:T111 Arg2:T9	
#100	AnnotatorNotes T111	C1302239; Patient consented to clinical trial; Finding
R26	Has_Age Arg1:T70 Arg2:T72	
R27	Has_Age Arg1:T71 Arg2:T72	
R28	Experiences Arg1:T73 Arg2:T10	
R30	Experiences Arg1:T73 Arg2:T53	
R32	Before Arg1:T12 Arg2:T11	
R34	Causes Arg1:T13 Arg2:T53	
R35	Has_Duration_or_Interval Arg1:T14 Arg2:T74	
R36	Has_Duration_or_Interval Arg1:T15 Arg2:T74	
R37	Has_Duration_or_Interval Arg1:T16 Arg2:T74	
R38	Experiences Arg1:T73 Arg2:T12	
R39	Experiences Arg1:T73 Arg2:T13	
R40	Experiences Arg1:T73 Arg2:T14	
R41	Experiences Arg1:T73 Arg2:T15	
R42	Experiences Arg1:T73 Arg2:T16	
R43	Experiences Arg1:T73 Arg2:T18	
T116	Result_or_Value 883 896	menor del 94%
R44	Has_Result_or_Value Arg1:T18 Arg2:T116	
R45	Causes Arg1:T13 Arg2:T14	
R46	Causes Arg1:T13 Arg2:T16	
R51	Overlap Arg1:T10 Arg2:T18	
R52	Experiences Arg1:T76 Arg2:T78	
R53	Experiences Arg1:T77 Arg2:T78	
R54	Experiences Arg1:T76 Arg2:T17	
R55	Experiences Arg1:T77 Arg2:T17	
R56	Has_Duration_or_Interval Arg1:T17 Arg2:T79	
R57	After Arg1:T17 Arg2:T84	
R58	Has_Quantifier_or_Qualifier Arg1:T84 Arg2:T96	
#101	AnnotatorNotes T96	C1517741; Last; Qualitative Concept 
T117	PROC 1000 1007	estudio
#102	AnnotatorNotes T117	C0008976; Clinical Trials; Research Activity
R59	Overlap Arg1:T17 Arg2:T117	
R60	Experiences Arg1:T80 Arg2:T81	
R61	Experiences Arg1:T80 Arg2:T20	
R62	Experiences Arg1:T80 Arg2:T106	
T118	CONC 1197 1206	inclusión
#103	AnnotatorNotes T118	C1512693; Inclusion; Qualitative Concept
R63	Overlap Arg1:T20 Arg2:T118	
R64	Overlap Arg1:T106 Arg2:T118	
R65	Overlap Arg1:T81 Arg2:T118	
R66	Before Arg1:T81 Arg2:T106	
T119	Observation 1246 1287	participando en algún otro ensayo clínico
R67	Experiences Arg1:T83 Arg2:T22	
R68	Experiences Arg1:T83 Arg2:T23	
R69	Used_for Arg1:T55 Arg2:T24	
R70	Experiences Arg1:T85 Arg2:T26	
T120	CONC 1487 1496	inclusión
#104	AnnotatorNotes T120	C1512693; Inclusion; Qualitative Concept
R71	Overlap Arg1:T26 Arg2:T120	
R72	Experiences Arg1:T86 Arg2:T27	
R73	Causes Arg1:T56 Arg2:T27	
R74	Causes Arg1:T28 Arg2:T27	
R75	Causes Arg1:T29 Arg2:T27	
R76	Causes Arg1:T30 Arg2:T27	
R77	Experiences Arg1:T87 Arg2:T31	
R78	Experiences Arg1:T87 Arg2:T32	
R79	Location_of Arg1:T57 Arg2:T33	
R80	Location_of Arg1:T57 Arg2:T34	
R81	Location_of Arg1:T57 Arg2:T35	
R82	Experiences Arg1:T88 Arg2:T33	
R83	Experiences Arg1:T88 Arg2:T34	
R84	Experiences Arg1:T88 Arg2:T35	
R85	Experiences Arg1:T88 Arg2:T36	
R86	Has_Duration_or_Interval Arg1:T36 Arg2:T89	
R87	Overlap Arg1:T33 Arg2:T36	
R88	Overlap Arg1:T34 Arg2:T36	
R89	Overlap Arg1:T35 Arg2:T36	
R90	Location_of Arg1:T58 Arg2:T37	
R92	Experiences Arg1:T90 Arg2:T37	
R93	Experiences Arg1:T90 Arg2:T19	
T121	Result_or_Value 1805 1809	< 30
R94	Has_Result_or_Value Arg1:T19 Arg2:T121	
T122	Quantifier_or_Qualifier 1790 1799	estadio 4
R95	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T122	
T123	Quantifier_or_Qualifier 1782 1788	severa
#105	AnnotatorNotes T123	C1547227; Severe - Severity of Illness Code; Intellectual Product
R96	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T123	
R97	Used_for Arg1:T59 Arg2:T38	
R98	Experiences Arg1:T91 Arg2:T38	
R99	Experiences Arg1:T92 Arg2:T40	
R100	Causes Arg1:T60 Arg2:T40	
R101	Experiences Arg1:T92 Arg2:T41	
R102	Experiences Arg1:T92 Arg2:T47	
R103	Overlap Arg1:T53 Arg2:T15	
R104	Overlap Arg1:T53 Arg2:T16	
A7	Experiencer T66 Patient
A8	Experiencer T69 Patient
A9	Experiencer T70 Patient
A10	Experiencer T71 Patient
A11	Experiencer T73 Patient
A12	Experiencer T76 Patient
A13	Experiencer T77 Patient
A14	Experiencer T80 Patient
A15	Experiencer T83 Patient
A16	Experiencer T85 Patient
A17	Experiencer T86 Patient
A18	Experiencer T87 Patient
A19	Experiencer T88 Patient
A20	Experiencer T90 Patient
A21	Experiencer T91 Patient
A22	Experiencer T92 Patient
A23	Experiencer T97 Other
A24	Experiencer T95 Patient
A25	Experiencer T98 Patient
A26	Experiencer T101 Patient
A27	Experiencer T103 Patient
A28	Status T63 Future
A29	Status T54 Future
A30	Status T102 Future
A31	Status T105 Future
T124	Result_or_Value 1168 1176	negativa
R6	Has_Result_or_Value Arg1:T20 Arg2:T124	
